An Intermediate Size Patient Population Expanded Access IND to Evaluate the Safety of Autologous HB-adMSCs for the Treatment of Patients With Parkinson's Disease
Latest Information Update: 09 May 2023
At a glance
- Drugs Autologous adipose derived mesenchymal stem cells Hope Biosciences (Primary)
- Indications Parkinson's disease
- Focus Expanded access; Therapeutic Use
- Sponsors Hope Biosciences
- 29 Jul 2022 Status changed from completed to recruiting.
- 17 Mar 2021 Status changed from suspended to completed.
- 04 Mar 2021 New trial record